183 related articles for article (PubMed ID: 22065721)
1. Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling.
Spitzer D; Simon PO; Kashiwagi H; Xu J; Zeng C; Vangveravong S; Zhou D; Chang K; McDunn JE; Hornick JR; Goedegebuure P; Hotchkiss RS; Mach RH; Hawkins WG
Cancer Res; 2012 Jan; 72(1):201-9. PubMed ID: 22065721
[TBL] [Abstract][Full Text] [Related]
2. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy.
Kashiwagi H; McDunn JE; Simon PO; Goedegebuure PS; Xu J; Jones L; Chang K; Johnston F; Trinkaus K; Hotchkiss RS; Mach RH; Hawkins WG
Mol Cancer; 2007 Jul; 6():48. PubMed ID: 17631687
[TBL] [Abstract][Full Text] [Related]
3. Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma.
Kashiwagi H; McDunn JE; Simon PO; Goedegebuure PS; Vangveravong S; Chang K; Hotchkiss RS; Mach RH; Hawkins WG
J Transl Med; 2009 Mar; 7():24. PubMed ID: 19323815
[TBL] [Abstract][Full Text] [Related]
4. Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells.
Zhang Y; Huang Y; Zhang P; Gao X; Gibbs RB; Li S
Int J Nanomedicine; 2012; 7():4473-85. PubMed ID: 22927761
[TBL] [Abstract][Full Text] [Related]
5. Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer.
Hornick JR; Vangveravong S; Spitzer D; Abate C; Berardi F; Goedegebuure P; Mach RH; Hawkins WG
J Exp Clin Cancer Res; 2012 May; 31(1):41. PubMed ID: 22551149
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands.
Hornick JR; Spitzer D; Goedegebuure P; Mach RH; Hawkins WG
Surgery; 2012 Sep; 152(3 Suppl 1):S152-6. PubMed ID: 22763259
[TBL] [Abstract][Full Text] [Related]
7. Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134.
Hashim YM; Spitzer D; Vangveravong S; Hornick MC; Garg G; Hornick JR; Goedegebuure P; Mach RH; Hawkins WG
Mol Oncol; 2014 Jul; 8(5):956-67. PubMed ID: 24731702
[TBL] [Abstract][Full Text] [Related]
8. Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic.
Ohman KA; Hashim YM; Vangveravong S; Nywening TM; Cullinan DR; Goedegebuure SP; Liu J; Van Tine BA; Tiriac H; Tuveson DA; DeNardo DG; Spitzer D; Mach RH; Hawkins WG
Oncotarget; 2016 Jun; 7(23):33529-41. PubMed ID: 27244881
[TBL] [Abstract][Full Text] [Related]
9. Sigma-2 ligands induce tumour cell death by multiple signalling pathways.
Zeng C; Rothfuss J; Zhang J; Chu W; Vangveravong S; Tu Z; Pan F; Chang KC; Hotchkiss R; Mach RH
Br J Cancer; 2012 Feb; 106(4):693-701. PubMed ID: 22251921
[TBL] [Abstract][Full Text] [Related]
10. Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer.
Pati ML; Hornick JR; Niso M; Berardi F; Spitzer D; Abate C; Hawkins W
BMC Cancer; 2017 Jan; 17(1):51. PubMed ID: 28086830
[TBL] [Abstract][Full Text] [Related]
11. The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine.
Hornick JR; Xu J; Vangveravong S; Tu Z; Mitchem JB; Spitzer D; Goedegebuure P; Mach RH; Hawkins WG
Mol Cancer; 2010 Nov; 9():298. PubMed ID: 21092190
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic sigma-2 ligands trigger cancer cell death via cholesterol-induced-ER-stress.
Takchi R; Prudner BC; Gong Q; Hagi T; Newcomer KF; Jin LX; Vangveravong S; Van Tine BA; Hawkins WG; Spitzer D
Cell Death Dis; 2024 May; 15(5):309. PubMed ID: 38697978
[TBL] [Abstract][Full Text] [Related]
13. Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells.
McDonald ES; Mankoff J; Makvandi M; Chu W; Chu Y; Mach RH; Zeng C
Biochem Biophys Res Commun; 2017 May; 486(3):788-795. PubMed ID: 28347815
[TBL] [Abstract][Full Text] [Related]
14. SV119-gold nanocage conjugates: a new platform for targeting cancer cells via sigma-2 receptors.
Wang Y; Xu J; Xia X; Yang M; Vangveravong S; Chen J; Mach RH; Xia Y
Nanoscale; 2012 Jan; 4(2):421-4. PubMed ID: 22113350
[TBL] [Abstract][Full Text] [Related]
15. Sigma-2 receptor ligands and their perspectives in cancer diagnosis and therapy.
Huang YS; Lu HL; Zhang LJ; Wu Z
Med Res Rev; 2014 May; 34(3):532-66. PubMed ID: 23922215
[TBL] [Abstract][Full Text] [Related]
16. Using SV119-gold nanocage conjugates to eradicate cancer stem cells through a combination of photothermal and chemo therapies.
Sun T; Wang Y; Wang Y; Xu J; Zhao X; Vangveravong S; Mach RH; Xia Y
Adv Healthc Mater; 2014 Aug; 3(8):1283-91. PubMed ID: 24677807
[TBL] [Abstract][Full Text] [Related]
17. Divergent Cytotoxic and Metabolically Stimulative Functions of Sigma-2 Receptors: Structure-Activity Relationships of 6-Acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[
Nicholson HE; Alsharif WF; Comeau AB; Mesangeau C; Intagliata S; Mottinelli M; McCurdy CR; Bowen WD
J Pharmacol Exp Ther; 2019 Feb; 368(2):272-281. PubMed ID: 30530624
[TBL] [Abstract][Full Text] [Related]
18. Potential applications for sigma receptor ligands in cancer diagnosis and therapy.
van Waarde A; Rybczynska AA; Ramakrishnan NK; Ishiwata K; Elsinga PH; Dierckx RA
Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2703-14. PubMed ID: 25173780
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of sigma-receptor ligands is associated with major changes of cellular metabolism and complete occupancy of the sigma-2 subpopulation.
Rybczynska AA; Dierckx RA; Ishiwata K; Elsinga PH; van Waarde A
J Nucl Med; 2008 Dec; 49(12):2049-56. PubMed ID: 18997057
[TBL] [Abstract][Full Text] [Related]
20. Fluorescent derivatives of σ receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) as a tool for uptake and cellular localization studies in pancreatic tumor cells.
Abate C; Hornick JR; Spitzer D; Hawkins WG; Niso M; Perrone R; Berardi F
J Med Chem; 2011 Aug; 54(16):5858-67. PubMed ID: 21744858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
